Crossmark

Survival advantage of treosulfan plus fludarabine (FT14) compared to busulfan plus fludarabine (FB4) in active acute myeloid leukemia post allogeneic transplantation: an analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP)

Crossref DOI link: https://doi.org/10.1038/s41409-023-02028-x

Published Online: 2023-07-07

Published Print: 2023-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gavriilaki, Eleni https://orcid.org/0000-0002-8883-8208
Sakellari, Ioanna

Labopin, Myriam https://orcid.org/0000-0003-4514-4748
Bornhäuser, Martin

Hamladji, Rose-Marie

Casper, Jochen

Edinger, Matthias

Zák, Pavel

Yakoub-Agha, Ibrahim https://orcid.org/0000-0003-4524-8782
Ciceri, Fabio https://orcid.org/0000-0003-0873-0123
Schroeder, Thomas

Zuckerman, Tsila https://orcid.org/0000-0002-6204-977X
Kobbe, Guido

Yeshurun, Moshe

Narni, Franco https://orcid.org/0000-0003-3994-9101
Finke, Jürgen https://orcid.org/0000-0002-1799-5927
Diez-Martin, Jose Luiz

Berceanu, Ana

Hilgendorf, Inken https://orcid.org/0000-0003-2038-9730
Verbeek, Mareike

Olivieri, Attilio

Savani, Bipin

Spyridonidis, Alexandros

Nagler, Arnon https://orcid.org/0000-0002-0763-1265
Mohty, Mohamad https://orcid.org/0000-0002-7264-808X
License Information

Text and Data Mining valid from 2023-07-07

Version of Record valid from 2023-07-07
More Information

Article History

Received: 8 February 2023

Revised: 2 June 2023

Accepted: 26 June 2023

First Online: 7 July 2023

Competing interests

: The authors declare no competing interests.

Document is current

Any future updates will be listed below